<DOC>
	<DOCNO>NCT02326025</DOCNO>
	<brief_summary>The purpose study ass body handle olaratumab give another drug call doxorubicin . The safety tolerability drug study . Each participant complete two 21-day cycle fix order . Participants complete Cycle 2 may continue receive olaratumab + doxorubicin additional six 21-day cycle may receive olaratumab alone discontinuation criterion meet . Screening require within 21 day prior first dose . Part B add October , 2015 ass body handle high dose olaratumab give doxorubicin . Participants may enroll one part .</brief_summary>
	<brief_title>A Study Olaratumab Doxorubicin Participants With Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Have histological cytological evidence diagnosis soft tissue sarcoma ( STS ) advance and/or metastatic Have presence measurable and/or nonmeasurable disease Have give write informed consent prior studyspecific procedure Have performance status less equal 2 Eastern Cooperative Oncology Group ( ECOG ) scale Have discontinue previous treatment cancer recover acute effect therapy Are reliable willing make available duration study willing follow study procedure Have receive treatment within 28 day initial dose study drug investigational product nonapproved use drug device noncancer indication Have receive prior treatment doxorubicin , daunorubicin , idarubicin , and/or anthracyclines anthracenediones Have active central nervous system ( CNS ) metastasis . Participants treat CNS metastasis eligible study currently receive corticosteroid Part A participant : Have current hematologic malignancy , acute chronic leukemia Have unstable hepatic disease grade equal great ChildPugh B Have active fungal , bacterial , and/or know viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis Have history another primary cancer , exception ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor treat curative intent , know active disease present , treatment administer last 3 year prior study entry Have history chronic heart failure leave ventricular dysfunction Have rest heart rate le ( &lt; ) 50 beat per minute ( bpm ) great ( &gt; ) 100 bpm Have history radiation therapy involve mediastinal/pericardial area . Previous radiation therapy allow must include whole pelvis radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>